视丘下部性肥胖 - 开发平台分析:2023年

本报告提供视丘下部性肥胖的开发平台的相关调查，第一阶段，第二阶段，第三阶段的开发平台趋势，市场上竞争情形，法律规范趋势，开发平台的药物简介等彙整资讯。

目录

概要

视丘下部性肥胖的标的

• 简介
• 视丘下部性肥胖的流行病学与原因
• 视丘下部性肥胖的病理学
• 视丘下部性肥胖的治疗方法
• 治疗流程

视丘下部性肥胖的各阶段开发平台分析

• 视丘下部性肥胖的发病- 概要
• 开发中产品，各开发阶段
• 视丘下部性肥胖的竞争情形，各相
• 开发中产品，各企业
• 视丘下部性肥胖的单剂疗法和联合治疗的临床试验
• 开发中产品，各作用机制
• 视丘下部性肥胖临床及法规计划
• 后期阶段的简介的比较概要

视丘下部性肥胖症的授权，收购，及合作契约

视丘下部性肥胖开发平台的形势

• 视丘下部性肥胖开发平台的药物简介

第Ⅲ相

• Setmelanotide(Rhythm Pharmaceuticals)
• Exenatide(AstraZeneca)

第二阶段

• Tesomet (Saniona)

第一阶段

• GT-001(Gila Therapeutics, Inc)

前临床

• ENT-03(Enterin Inc)
• TRP-8802(Tryp Therapeutics)

视丘下部性肥胖的SWOT分析

附录

The Hypothalamic Obesity report covers the Hypothalamic Obesity market opportunity providing Key Competitive Analysis, 6 Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. In addition, our report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, mechanism of action, intervention types. The Hypothalamic Obesity report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

Hypothalamic obesity (HyOb) is a complex medical condition that can arise from the development of rare brain tumors or other forms of hypothalamic injury. Among the tumors that can give rise to HyOb, craniopharyngioma is a noteworthy example. Hypothalamic obesity is characterized by an abnormal hypothalamus function, a key aspect of which is its involvement in satiety and food intake regulation. Notably, damage to the ventromedial nucleus of the hypothalamus bilaterally can lead to a syndrome of HyOb that is typified by hyperphagia and obesity, as well as other endocrinal and neurological manifestations.

In this report, Mellalta Meets provides an in-depth analysis of Hypothalamic Obesity pipeline covering Phase III , Phase II & Phase I Pipeline Analysis Overview, Pipeline Products by Stage of Development, Hypothalamic Obesity Competitive Landscape Distinguished by Phase & Route and moleucle type, Clinical Pipeline Products by Company, Hypothalamic Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Hypothalamic Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are 6 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are AstraZeneca, Rhythm Pharmaceuticals, Saniona, Gila Therapeutics, which have robust clinical pipelines of Hypothalamic Obesity candidates.

As per analysis, the development pipeline is full of molecules like small molecules, and peptides.

Key Highlights of the Hypothalamic Obesity Report

• The Hypothalamic Obesity segment is dominated by the Phase 3 and pre-clinical assets (XX each) which represent XX% of the total development followed by XX each asset in Phase 1 and Phase 2 representing XX% of each of the pipeline development in Hypothalamic Obesity.

• The hypothalamic obesity treatment pipeline is marked by a strong presence of US-based biotech companies, accounting for an impressive XX% of all clinical-stage hypothalamic obesity therapies, followed by UK, Canada and Denmark with XX%.

• Hypothalamic Obesity pipeline landscape includes 100% of Monotherapy trials.

• The Hypothalamic Obesity segment is split equally between the pre-clinical and Phase 3 assets (2-2 each), phase 1 assets (2), and Phase 2 assets (2).

Report Coverage:

• Indication Prioritisation: Hypothalamic Obesity market potential based on Indications.

• Business Transactions & Strategies: Key collaborations and deal values

• Hypothalamic Obesity Pipeline Development: Product Profiles, Clinical Trials & Results

• Hypothalamic Obesity Acquisition Targets

• Hypothalamic Obesity Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The Hypothalamic Obesity Target BACKGROUND

• Introduction
• Epidemiology & Causes of hypothalamic obesity
• Pathophysiology of Hypothalamic Obesity
• Treatment Approach of Hypothalamic Obesity
• Treatment Algorithm

Hypothalamic Obesity PIPELINE ANALYSIS by Phases

• Hypothalamic Obesity Development - Overview
• Pipeline Products by Stage of Development
• Hypothalamic Obesity Competitive Landscape by Phases
• Pipeline Products by Company
• Hypothalamic Obesity Monotherapy & Combinations Clinical Trials
• Pipeline Products by MOA
• Hypothalamic Obesity Clinical & Regulatory Timelines
• Late-Stage Profiles Comparisons At-a-glance

Hypothalamic Obesity LICENSING, ACQUISITION, AND COLLABORATION DEALS

• Hypothalamic Obesity Licensing, Acquisition, and Deal values
• Hypothalamic Obesity Licensing by Transaction type and total amount size by Phases

Hypothalamic Obesity Pipeline Landscape

• Hypothalamic Obesity Pipeline Drug Profiles

Phase III

• Setmelanotide (Rhythm Pharmaceuticals)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Exenatide (AstraZeneca)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase II

• Tesomet (Saniona)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase I

• GT-001 (Gila Therapeutics, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Preclinical

• ENT-03 (Enterin Inc.)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• TRP-8802 (Tryp Therapeutics)
  • Product Profile & Description
  • Collaborations
  • Other Developments

Hypothalamic Obesity SWOT Analysis

Appendix

• About us